Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Brief Summary: The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.


Options:
A: Arm Label: Atacicept 150 mg with loading dose; Type: EXPERIMENTAL; Interventions: Drug: Atacicept: with loading dose | Arm Label: Atacicept 150 mg without loading dose; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atacicept: with loading dose; Assigned to Arm(s): Atacicept 150 mg with loading dose | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg without loading dose | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: Tocilizumab 4 mg/kg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: Tocilizumab 8 mg/kg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab 4 mg/kg + Methotrexate, Tocilizumab 8 mg/kg + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Tocilizumab 4 mg/kg + Methotrexate, Tocilizumab 8 mg/kg + Methotrexate
C: Arm Label: Subcutaneous (SC) abatacept, 125 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) abatacept | Arm Label: Intravenous (IV) abatacept, 125 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) abatacept | Intervention Type: DRUG; Name: Intravenous (IV) abatacept; Assigned to Arm(s): Intravenous (IV) abatacept, 125 mg | Intervention Type: DRUG; Name: Subcutaneous (SC) abatacept; Assigned to Arm(s): Subcutaneous (SC) abatacept, 125 mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3

Answer: A